Sylatron

Drug - Sylatron (peginterferon alfa-2b) [Merck]

November 2011

Therapeutic Area - Oncology

Approval criteria

Patient has melanoma with microscopic or gross nodal involvement AND
Patient had definitive surgical resection or complete lymphadenectomy within last 84 days

Exclusion criteria

Patient history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b OR
autoimmune hepatitis OR
hepatic decompensation (Child-Pugh score >6 [class B and C])

Background information

SYLATRON is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411